The autoimmune disease treatment industry is projected to benefit from advancements in AID treatment. In 2016, researchers at the Perelman School of Medicine discovered a strategy to target a specific fraction of antibody that is responsible for the activation of the autoimmune illness pemphigus vulgaris (PV). The researchers developed chimeric autoantibody receptor treatment (CAART), which can be utilised to treat this disease without affecting the immune system's normal function.
Furthermore, in 2016, Cumming School of Medicine researchers discovered a new class of Nano-medicine to treat diseases such as type 1 diabetes, multiple sclerosis, and rheumatoid arthritis without affecting immunity. Parvus Therapeutics, Inc. is currently developing this Nano-medicine, which is being financed by Innovate Calgary.
Read More:
https://bloggerstrive.blogspot.com/2022/03/autoimmune-disease-treatment-market.html
Click here for Autoimmune Disease Treatment Market Report:
https://www.coherentmarketinsights.com/market-insight/autoimmune-disease-treatment-market-895
